AbbVie 8-K Details Officer Changes, Compensation, and Debt Structure

Ticker: ABBV · Form: 8-K · Filed: 2024-02-20T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, debt, officer-changes

Related Tickers: ABBV

TL;DR

**AbbVie just dropped an 8-K on officer changes, compensation, and a bunch of senior notes due from 2024 to 2031.**

AI Summary

AbbVie Inc. filed an 8-K on February 20, 2024, reporting on events that occurred on February 14, 2024. The filing details information regarding the departure or election of directors or officers, compensatory arrangements, and Regulation FD disclosure. It also lists various senior notes with different interest rates and maturity dates, including 1.375% due 2024, 1.250% due 2024, and 0.750% due 2027, all traded on the NYSE.

Why It Matters

This filing provides transparency into AbbVie's corporate governance and financial structure, specifically regarding its leadership and outstanding debt obligations, which can influence investor confidence and future financial performance.

Risk Assessment

Risk Level: low — The filing primarily provides routine updates on corporate governance and existing debt, without indicating any immediate significant risks or changes to the company's operations.

Key Numbers

Key Players & Entities

FAQ

What was the conformed period of report for this 8-K filing by AbbVie Inc.?

The conformed period of report for this 8-K filing was February 14, 2024.

What types of information were included in the ITEM INFORMATION section of AbbVie's 8-K?

The ITEM INFORMATION section included 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.

What are the interest rates and maturity dates for some of AbbVie's senior notes mentioned in the filing?

AbbVie has senior notes with a 1.375% interest rate due 2024, 1.250% due 2024, 0.750% due 2027, 2.125% due 2028, 2.625% due 2028, 2.125% due 2029, and 1.250% due 2031.

On which stock exchange are AbbVie's Common Stock and Senior Notes traded, according to the filing?

AbbVie's Common Stock and Senior Notes are traded on the NYSE (XNYS).

What is AbbVie Inc.'s Central Index Key (CIK) as stated in the filing?

AbbVie Inc.'s Central Index Key (CIK) is 0001551152.

From the Filing

0001104659-24-025262.txt : 20240220 0001104659-24-025262.hdr.sgml : 20240220 20240220090041 ACCESSION NUMBER: 0001104659-24-025262 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24651052 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm246649d1_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-14 2024-02-14 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-14 2024-02-14 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-14 2024-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): February 14, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1 North Waukegan Road     North Chicago , Illinois   60064-6400 (Address of principal executive offices)   (Zip Code)   ( 847 ) 932-7900 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange 1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28  

View on Read The Filing